Emergent BioSolutions Inc. provided earnings guidance for the full year 2022. For the year, the company expects total revenues of $1,400 million to $1,500 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.84 USD | +9.61% |
|
+35.69% | +348.33% |
Jul. 09 | Emergent Biosolutions, Johnson & Johnson Settle Dispute Over COVID-19 Vaccine Manufacturing | MT |
Jul. 08 | Emergent, J&J settle COVID vaccine supply deal dispute | RE |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+348.33% | 518M | |
+62.61% | 841B | |
+40.42% | 625B | |
-4.04% | 360B | |
+17.43% | 327B | |
+10.42% | 300B | |
+15.66% | 242B | |
+17.90% | 227B | |
+15.79% | 174B | |
+0.96% | 162B |
- Stock Market
- Equities
- EBS Stock
- News Emergent BioSolutions Inc.
- Emergent BioSolutions Inc. Provides Earnings Guidance for the Full Year 2022